Clinical trials: Adenosine
Pulmonary Alveolar Proteinosis
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis
This observational study was designed as a prospective epidemiological screening study. Patients who have applied to the centers participating in the study and who have previously been clinically or pathologically diagnosed with…
- Trial name
- NCT05300360
- Testing
- adenosine deaminase test
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- TRPHARM
Chest Pain, Severe Aortic Stenosis
Myocardial Flow Reserve in Severe AS Without Obstructive Coronary Artery Disease
Exertional angina is common symptom in patients with severe aortic stenosis (AS) without obstructive coronary artery disease (CAD).
- Trial name
- NCT02575768
- Testing
- Adenosine-stress cardiac magnetic resonance imaging
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Pancreatic Cancer
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in…
- Trial name
- NCT06119217
- Testing
- TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, Nab-Paclitaxel and gemcitabine
- Where
- 64 sites in United States, Australia and 5 more
- Volunteers
- 194 people
- Sponsor
- Trishula Therapeutics, Inc.
Asthma
Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate
Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether 5-days of treatment with fluticasone propionate protects the lung from responding to the AMP in this way.
- Trial name
- NCT00400855
- Testing
- Fluticasone propionate
- Where
- 2 sites in New Zealand
- Volunteers
- 49 people
- Sponsor
- GlaxoSmithKline
Healthy Experienced Weight Training Males
The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes
The purpose of this study is to determine the effects of 12 weeks of HMB free acid gel, ATP, and HMB free acid gel plus ATP supplementation in trained individuals during a periodized training program on skeletal muscle…
- Trial name
- NCT01508338
- Testing
- HMB, Peak ATP and HMB, ATP
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Metabolic Technologies Inc.
Acute Decompensated Heart Failure; Renal Dysfunction
Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure
The purpose of this study is to determine the efficacy and safety of IV SLV320 in acute heart failure patients with renal dysfunction.
- Trial name
- NCT00744341
- Testing
- SLV320
- Where
- 105 sites in United States, Canada and 9 more
- Volunteers
- 46 people
- Sponsor
- Solvay Pharmaceuticals
Coronary Artery Disease
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
- Trial name
- NCT00208299
- Testing
- Regadenoson, Adenosine
- Where
- United States
- Volunteers
- 1,231 people
- Sponsor
- Gilead Sciences
Ovarian Cancer, Fallopian Tube Cancer
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT05200260
- Testing
- Primary debulking surgery, Neoadjuvant chemotherapy, PARP inhibitor
- Where
- 9 sites in China
- Volunteers
- 220 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Syncope
Theophylline for Low Adenosine Syncope
The study aims at assessing that theophylline is effective in patients with no prodromes, normal heart and with low values of plasmatic adenosine compared with a propensity-score matched untreated control population who have…
- Trial name
- THEO-USA (NCT03803215)
- Testing
- Theophylline
- Where
- Italy
- Volunteers
- 77 people
- Sponsor
- Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella
Olfactory Disorder
cAMP (Cyclic Adenosine Monophosphate) Levels in the Nose
The purpose of this study is to determine the normal distribution of nasal tissue cathelicidin antimicrobial peptides (cAMP) levels in subjects with normal smell and subjects with smell dysfunction.
- Trial name
- NCT01332825
- Testing
- saline nasal irrigation
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Washington
Myocardial Infarction, Myocardial Fibrosis
Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction
This is a single-center, prospective, observational controlled cohort study designed to describe the role of WNT/B-catenin signaling and adenosine system after an acute myocardial infarction, correlating it with clinical markers…
- Conditions
- Myocardial Infarction, Myocardial Fibrosis, Myocardial Remodeling, Ventricular
- Trial name
- BETA-MI (NCT05122741)
- Testing
- P2Y12 Potent Inhibitor + Aspirin for STEMI patients, Clopidogrel + Aspirin for CCS patients
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Messina
Parkinson Disease, Huntington Disease
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
The underlying goal of this study is to assess [123I]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.
- Trial name
- MNI-420 (NCT00970229)
- Testing
- [123I]MNI-420
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Asthma
"First-in-human" Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers
This is a phase I, single-center, randomized, double-blind, dose escalation study without therapeutic benefit, in which PBF-680 will be administered as single oral ascending dose to young male healthy volunteers.
- Trial name
- NCT01845181
- Testing
- PBF-680
- Where
- 2 sites in Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Ischemia-Reperfusion Injury
Adenosine Receptors Influence Ischemia-Reperfusion Injury
Ischemic preconditioning is defined as the development of tolerance to ischemia-reperfusion injury by a previous short bout of ischemia resulting in a marked reduction in infarct size.
- Trial name
- NCT00184847
- Testing
- acetylcholine, twenty minutes of forearm ischemia, three 5-minute periods of forearm ischemia
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
This trial studies the best dose and side effects of utomilumab (4-1BB agonist monoclonal antibody PF-05082566) with trastuzumab emtansine or trastuzumab in treating patients with HER2-positive breast cancer that has spread to…
- Conditions
- HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT03364348
- Testing
- Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- George W. Sledge Jr.
Heart Failure
Multiple Dose Study in Heart Failure of BAY 1067197
This is a study to investigate the safety, tolerability and early effects on cardiac function of the partial A1 agonist BAY1067197 in patients with chronic heart failure.
- Trial name
- PARSiFAL (NCT02040233)
- Testing
- BAY1067197 (10 mg), BAY1067197
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 31 people
- Sponsor
- Bayer
Bronchiectasis, Adenosine Deaminase Deficiency
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA)
This observational study was designed as a prospective epidemiological screening study. Patients who applied to the centers participating in the study, bronchiectasis was detected on at least one computed tomography of the lungs…
- Conditions
- Bronchiectasis, Adenosine Deaminase Deficiency, Pulmonary Disease
- Trial name
- NCT05300347
- Testing
- adenosine deaminase enzyme deficiency test
- Where
- Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- TRPHARM
Percutaneous Coronary Intervention
Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
The purpose of this study is to compare FFR measurements done with adenosine to FFR measurements done with contrast, where the contrast is injected using the ACIST CVi automated contrast injector.
- Trial name
- ACCELERATION (NCT03557385)
- Testing
- Iopamidol, adenosine, Navvus® Catheter
- Where
- 5 sites in United States
- Volunteers
- 201 people
- Sponsor
- Duke University
Glioma Glioblastoma Multiforme
Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma
Phase I open-label trial of 123I-ATT001 monotherapy and in combination with treatment therapies in subjects with relapsed glioblastoma.
- Trial name
- CITADEL-123 (NCT06650605)
- Testing
- 123I-ATT001
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Theragnostics Ltd
Heart Failure, Congestive
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00328692
- Testing
- rolofylline
- Volunteers
- 932 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)